Plasma as endothelial rescue in septic shock: A randomized, phase 2a pilot trial

Abstract

AbstractBackgroundSeptic shock is associated with high morbidity and mortality, the endothelium plays an important role. Crystalloids is standard of care to maintain intravascular volume. Plasma is associated with improved endothelial integrity and restoration of the glycocalyx layer. We evaluated the efficacy and safety aspects of cell‐free and pathogen inactivated pooled plasma (OctaplasLG®) as resuscitation in septic shock patients.Study Design and MethodsThis randomized, investigator‐initiated phase IIa trial ran at a Danish single center intensive care unit, from 2017 to 2019. Patients were 18 years of age or older with septic shock and randomized to fluid optimization with OctaplasLG® or Ringer‐acetate in the first 24 h. The primary endpoints were changes in biomarkers indicative of endothelial activation, damage, and microvascular perfusion from baseline to 24 h. Safety events and mortality were assessed during 90 days.ResultsForty‐four patients were randomized, 20 to OctaplasLG versus 24 to Ringer‐acetate. The median age was 69, and 55% were men. Median Sequential Organ Failure Assessment score was 13. Baseline differences favoring the Ringer‐acetate group were observed. The OctaplasLG® group was resuscitated with 740 mL plasma and the Ringer‐acetate group with 841 mL crystalloids. There was no significant change in the microvascular perfusion or five biomarkers except VEGFR1 change, which was higher in patients receiving OctaplasLG® 0.12(SD 0.37) versus Ringer‐acetate −0.24 (SD 0.39), with mean difference 0.36 (95% CI, 0.13–0.59, p = .003) in favor of Ringer‐acetate.DiscussionThis study found that fluid resuscitation with OctaplasLG® in critically ill septic shock patients is feasible. Baseline confounding prevented assessment of the potential effect of OctaplasLG®.